Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Duchene Muscular Dystrophy, Becker Muscular Dystrophy. Basic parameters: 5 years — 60 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Multiparametric Ultrafast Ultrasound Evaluation of Skeletal Muscle in Duchenne and Becker Muscular Dystrophies
Overview
The purpose of this research study is to determine the potential of a multiparametric ultrasound approach to non-invasively monitor disease progression and to serve as an objective outcome measure for future clinical trials in Duchenne and Becker Muscular Dystrophies. The investigators will compare the muscles of ambulatory or non-ambulatory boys/men with Duchenne and Becker Dystrophies with muscles of healthy age-matched individuals of the same age and monitor disease progression in those with muscular dystrophies over a 12-month year period. The ultrafast ultrasound technology used in this study allows the simultaneous assessment of muscle structure, mechanics and physiology, including stiffness, anisotropy, viscosity, intramuscular fat, muscle volume, and microvascular perfusion. The amount of muscle alteration measured will be related to performance in daily activities, such as walking and muscle strength, in order to identify sensitive and objective markers of disease progression.
Detailed description
Duchenne and Becker muscular dystrophies (DMD/BMD) are the most common forms of muscular dystrophies, progressive muscle wasting diseases leading to weakness and devastating functional impairment. DMD is characterized by predominant involvement in skeletal, including respiratory, and cardiac muscles. Diagnosis is usually established at three to four years of age. Patients typically show muscle degeneration that worsens with age, leading to wheelchair dependency usually by the age of ten, assisted ventilation before the age of twenty, and premature death in the second to fourth decade. BMD shows a similar clinical phenotype but a later onset (approximately twelve years of age), a slower disease progression, delayed or no loss of ambulation, and variable involvement of the cardiac and respiratory systems. Considerable heterogeneity has been observed within and across the DMD/BMD phenotypes, which makes the design and analysis of clinical trials and prediction of the disease progression challenging.
Recent inconsistent results in DMD clinical development programs have also raised questions about the validity of the methods used to evaluate treatment efficacy. The number of potentially effective therapeutic approaches for DMD/BMD has rapidly increased over recent years, and thus the demand for validated outcome measures to demonstrate clinically meaningful therapeutic response over time in clinical trials (e.g., one year) is higher than ever. Regulatory agencies (e.g., FDA) have explicitly been encouraging the development of imaging biomarkers that may serve as surrogate markers of how patients will respond to investigational treatments in DMD/BMD.
This study aims to validate the potential of innovative ultrasound imaging methods, developed by our research consortium over recent years, as imaging tools to monitor disease progression and serve as a surrogate outcome measure for clinical trials in muscular dystrophies. Using cutting-edge ultrasound imaging techniques, including shear wave elastography, matrix approach, 3D freehand ultrasound, and power Doppler we will quantify much needed surrogate measures of muscle damage and progressive degeneration such as intramuscular fat content, fibrosis, muscle apoptosis and structural disorganization, inflammation, hypertrophy/atrophy, and intramuscular blood flow, in the lower and upper extremity muscles. An easy-to-apply multiparametric approach will be developed to assess the most important hallmarks of muscle degeneration associated with the most common and devastating muscular dystrophies.
Primary outcome measures
- Baseline mechanical, structural, and physiological muscle ultrasound parameters [Time frame: Baseline]
- Baseline mechanical, structural, and physiological muscle ultrasound parameters [Time frame: Baseline]
- Baseline mechanical, structural, and physiological muscle ultrasound parameters [Time frame: Baseline]
- Baseline mechanical, structural, and physiological muscle ultrasound parameters [Time frame: Baseline]
- Baseline mechanical, structural, and physiological muscle ultrasound parameters [Time frame: Baseline]
- Baseline mechanical, structural, and physiological muscle ultrasound parameters [Time frame: Baseline]
Secondary outcome measures (10)
- Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters [Time frame: 12 months]
- Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters [Time frame: 12 months]
- Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters [Time frame: 12 months]
- Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters [Time frame: 12 months]
- Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters [Time frame: 12 months]
- Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters [Time frame: 12 months]
- Muscle function [Time frame: Baseline and changes from baseline in at 12 months]
- Functional outcomes [Time frame: Baseline and changes from baseline at 12 months]
- Functional outcomes [Time frame: Baseline and changes from baseline at 12 months]
- Correlations between ultrasound measures, muscle function and functional outcomes [Time frame: Through study completion, 12 months]
Eligibility criteria
Inclusion criteria
- Inclusion Criteria for patients with Duchenne Muscular Dystrophy: Ambulatory and non-ambulatory males (ages 5-30 at baseline testing) previously diagnosed with Duchenne Muscular Dystrophy based on absence of dystrophin expression.
- Inclusion Criteria for patients with Becker Muscular Dystrophy: Ambulatory and non-ambulatory males (ages 5-60 at baseline testing) previously diagnosed with Becker Muscular Dystrophy based on genetically confirmed, reduced or dysfunctional dystrophin.
- Inclusion Criteria for Aged-matched controls: Ambulatory males (ages 5-60 years) without disease or injury to the lower and/or upper extremities
Exclusion criteria
- Exclusion Criteria for patients with Duchenne and Becker Muscular Dystrophies:
Inability to undergo static exam, missing measurement site (resection/amputation), neurocognitive impairment preventing informed consent
- Exclusion Criteria for Age-matched controls: Any condition affecting muscle metabolism/function, neuromuscular disease, or injury to the lower and/or upper extremities in the past 5 years
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Other
Study locations
France · 1 center
- CHU de Nantes — Nantes
Identifiers
NCT: NCT07378553 · RC25_0273 · 2025-A01398-41